TrialsgrambetaRCTs are beautiful

Heart failure

GDMT pillars, ARNI, the SGLT2i era, HFpEF, cardiomyopathy and exercise training.

Trials
30
Years
1987–2025
Sort
  • 2025Ex-DHF⁠Exercise trainingIn 322 patients with heart failure and preserved ejection fraction, 12 months of supervised endurance and resistance training did not significantly improve a hierarchical composite of death, hospitalisation, peak oxygen uptake, diastolic function and symptoms compared with usual care, although peak oxygen uptake and NYHA class improved.20.5% vs 8.1%Read →
  • 2024FINEARTS-HF⁠MRAIn 6,001 patients with heart failure and an ejection fraction ≥ 40 %, finerenone reduced worsening-heart-failure events and cardiovascular death compared with placebo.IRR 0.84Read →
  • 2024ATTRibute-CM⁠TTR stabiliserIn 632 patients with transthyretin amyloid cardiomyopathy, acoramidis improved a hierarchical composite of death, CV hospitalisation, NT-proBNP and 6-minute walk distance compared with placebo.WR 1.895% CI 1.4-2.2Read →
  • 2024SEQUOIA-HCM⁠myosin inhibitorIn 282 patients with symptomatic obstructive HCM, aficamten improved peak oxygen uptake on exercise testing compared with placebo.Read →
  • 2023STEP-HFpEF⁠GLP-1 RAIn 529 patients with HFpEF (EF ≥ 45%) and obesity (BMI ≥ 30) without diabetes, semaglutide 2.4 mg improved heart-failure symptoms (KCCQ) and body weight compared with placebo.Read →
  • 2022DELIVER⁠SGLT2 inhibitorsIn 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.HR 0.82Read →
  • 2022STRONG-HF⁠GDMT up-titrationIn 1,078 patients recently hospitalised for acute heart failure, rapid up-titration of guideline-directed therapy with close follow-up reduced 180-day death or heart-failure readmission compared with usual care.RR 0.6695% CI 0.50-0.86Read →
  • 2022VALOR-HCM⁠myosin inhibitorIn 112 patients with obstructive HCM referred for septal reduction therapy, mavacamten reduced the need to proceed with or remain eligible for septal reduction therapy compared with placebo.17.9% vs 76.8%Read →
  • 2021EMPEROR-Preserved Core⁠SGLT2 inhibitorsIn 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.HR 0.7995% CI 0.69-0.90Read →
  • 2020EMPEROR-Reduced⁠SGLT2 inhibitorsIn 3,730 patients with HFrEF (EF ≤ 40 %), empagliflozin reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.75Read →
  • 2020EXPLORER-HCM⁠myosin inhibitorIn 251 patients with symptomatic obstructive HCM (NYHA II-III, LVOT gradient ≥50 mmHg), mavacamten improved the composite of peak VO2 and NYHA functional class compared with placebo.37% vs 17%Read →
  • 2020VICTORIA⁠sGC stimulatorIn 5,050 patients with worsening HFrEF (EF < 45%), vericiguat reduced cardiovascular death or first heart-failure hospitalisation compared with placebo.HR 0.9095% CI 0.82-0.98Read →
  • 2019DAPA-HF Core⁠SGLT2 inhibitorsIn 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.HR 0.74Read →
  • 2019PIONEER-HF⁠ARNIIn 881 patients hospitalised for acute decompensated HFrEF, in-hospital initiation of sacubitril/valsartan lowered NT-proBNP more than enalapril.-46.7% vs -25.3%Read →
  • 2018ATTR-ACT Core⁠CardiomyopathyIn 441 patients with transthyretin amyloid cardiomyopathy, tafamidis reduced all-cause mortality and cardiovascular hospitalisation compared with placebo.HR 0.7Read →
  • 2017RESET-HCM⁠Exercise in cardiomyopathyIn 136 adults with hypertrophic cardiomyopathy, 16 weeks of moderate-intensity aerobic exercise training produced a small increase in peak oxygen consumption, with no ventricular arrhythmias, compared with usual activity.Read →
  • 2017SMARTEX-HF⁠Exercise intensityIn 261 patients with heart failure and reduced ejection fraction, 12 weeks of supervised high-intensity interval training produced no greater reverse remodelling or gain in left ventricular end-diastolic diameter and peak oxygen uptake than moderate continuous training.Read →
  • 2016STICH⁠CABGIn 1,212 patients with ischaemic cardiomyopathy (EF ≤ 35%) and CAD, coronary-artery bypass grafting plus medical therapy reduced 10-year all-cause mortality compared with medical therapy alone.HR 0.8495% CI 0.73-0.97Read →
  • 2014PARADIGM-HF Core⁠ARNIIn 8,442 patients with HFrEF (EF ≤ 0.40), sacubitril/valsartan reduced CV death or hospitalisation for HF compared with enalapril.HR 0.8Read →
  • 2014TOPCAT⁠MRAIn 3,445 patients with HFpEF (EF ≥ 45%), spironolactone did not significantly reduce cardiovascular death, aborted cardiac arrest, or heart-failure hospitalisation compared with placebo.HR 0.8995% CI 0.77-1.04Read →
  • 2011EMPHASIS-HF⁠MRAIn 2,737 patients with mild HFrEF (NYHA II, EF ≤ 35 %), eplerenone reduced cardiovascular death or heart-failure hospitalisation compared with placebo.HR 0.63Read →
  • 2010SHIFT⁠If-channel inhibitorIn 6,558 patients with HFrEF (EF ≤ 35%) in sinus rhythm with heart rate ≥ 70 bpm, ivabradine reduced cardiovascular death or hospitalisation for worsening heart failure compared with placebo.HR 0.8295% CI 0.75-0.90Read →
  • 2009HF-ACTION⁠Exercise trainingIn 2,331 patients with heart failure and reduced ejection fraction, a supervised aerobic exercise-training programme did not significantly reduce all-cause mortality or hospitalisation compared with usual care.HR 0.9395% CI 0.84-1.02Read →
  • 2004A-HeFT⁠hydralazine/nitrateIn 1,050 Black patients with NYHA III-IV HFrEF on standard therapy, fixed-dose isosorbide dinitrate plus hydralazine improved a composite of survival, HF hospitalisation and quality of life compared with placebo.HR 0.57Read →
  • 2003CHARM⁠ARBIn 7,601 patients with symptomatic chronic heart failure, candesartan reduced cardiovascular death and heart-failure hospitalisation compared with placebo.HR 0.9195% CI 0.83-1.00Read →
  • 2001COPERNICUS⁠beta-blockerIn 2,289 patients with severe heart failure and EF ≤ 25%, carvedilol reduced all-cause mortality compared with placebo.11.2% vs 16.8%Read →
  • 1999MERIT-HF Core⁠Beta-blockadeIn 3,991 patients with HFrEF (EF ≤ 0.40, NYHA II–IV), metoprolol CR/XL reduced all-cause mortality compared with placebo.Read →
  • 1999RALES Core⁠MRAIn 1,663 patients with severe HFrEF on ACEi, spironolactone 25 mg reduced all-cause mortality compared with placebo.RR 0.7095% CI 0.60-0.82Read →
  • 1991SOLVD⁠ACE inhibitorIn 2,569 patients with symptomatic heart failure and EF ≤ 0.35, enalapril reduced all-cause mortality compared with placebo.35.2% vs 39.7%Read →
  • 1987CONSENSUS Core⁠RAAS inhibitionIn 253 patients with NYHA IV heart failure, enalapril reduced 6-month mortality versus placebo.26% vs 44%Read →